Poly(β-amino ester)-based 3D printed devices for oral biotherapeutic delivery: effect of composition and geometry

Atabak Ghanizadeh Tabriz – Research Fellow, University of Nottingham; Jonathan Booth – Engineering Technician, AstraZeneca Macclesfield, United Kingdom; Susanna Abrahmsén-Alami – Senior Principal Scientist, AstraZeneca, Gothenburg, Sweden; Nigel Davies – Senior Principal Scientist, AstraZeneca, Gothenburg, Sweden; Morgan Alexander – Professor of Biomedical Surfaces, University of Nottingham; Ricky Wildman – Professor in Chemical Engineering, University of Nottingham; Clive Roberts – Head of School of Life Science, University of Nottingham; Cameron Alexander – Professor of Polymer Therapeutics, University of Nottingham

Introduction:

Despite the tremendous progress toward the delivery of biotherapeutics, such as peptides and oligonucleotides, their effective oral delivery remains challenging, primarily due to low bioavailability (1). 3D-printed drug delivery systems offer a promising alternative for designing and manufacturing cost-effective, flexible delivery devices that enable personalised applications through customisation of geometry, dose, and release profile (3,4). Here, we present the development of 3D-printed devices based on a poly(β-amino ester) [PBAE] macromonomer that could be used as expandable delivery devices for oral delivery of peptides into the small intestine.